1. Home
  2. ATYR vs ALTI Comparison

ATYR vs ALTI Comparison

Compare ATYR & ALTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • ALTI
  • Stock Information
  • Founded
  • ATYR 2005
  • ALTI 2020
  • Country
  • ATYR United States
  • ALTI United States
  • Employees
  • ATYR N/A
  • ALTI N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • ALTI Investment Managers
  • Sector
  • ATYR Health Care
  • ALTI Finance
  • Exchange
  • ATYR Nasdaq
  • ALTI Nasdaq
  • Market Cap
  • ATYR 330.7M
  • ALTI 283.9M
  • IPO Year
  • ATYR 2015
  • ALTI N/A
  • Fundamental
  • Price
  • ATYR $3.87
  • ALTI $2.96
  • Analyst Decision
  • ATYR Strong Buy
  • ALTI
  • Analyst Count
  • ATYR 6
  • ALTI 0
  • Target Price
  • ATYR $18.60
  • ALTI N/A
  • AVG Volume (30 Days)
  • ATYR 1.9M
  • ALTI 127.1K
  • Earning Date
  • ATYR 03-13-2025
  • ALTI 03-13-2025
  • Dividend Yield
  • ATYR N/A
  • ALTI N/A
  • EPS Growth
  • ATYR N/A
  • ALTI N/A
  • EPS
  • ATYR N/A
  • ALTI N/A
  • Revenue
  • ATYR $235,000.00
  • ALTI $206,935,000.00
  • Revenue This Year
  • ATYR $1,387.23
  • ALTI $25.79
  • Revenue Next Year
  • ATYR $873.22
  • ALTI $9.88
  • P/E Ratio
  • ATYR N/A
  • ALTI N/A
  • Revenue Growth
  • ATYR N/A
  • ALTI N/A
  • 52 Week Low
  • ATYR $1.42
  • ALTI $2.33
  • 52 Week High
  • ATYR $4.66
  • ALTI $6.36
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 54.37
  • ALTI 39.03
  • Support Level
  • ATYR $2.98
  • ALTI $2.33
  • Resistance Level
  • ATYR $4.32
  • ALTI $3.11
  • Average True Range (ATR)
  • ATYR 0.39
  • ALTI 0.31
  • MACD
  • ATYR 0.06
  • ALTI -0.02
  • Stochastic Oscillator
  • ATYR 72.14
  • ALTI 48.10

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About ALTI AlTi Global Inc.

AlTi Global Inc is an independent wealth and asset manager providing entrepreneurs, multi-generational families, institutions, and emerging next-generation leaders with fiduciary capabilities as well as alternative investment strategies and advisory services. The firm has business which is organized into two business segments that includes Wealth Management and Strategic Alternatives. Wealth Management includes providing holistic solutions for their wealth management clients through their comprehensive range of wealth management services, including investment management and advisory services. Strategic Alternatives segment, it assists their investors with alternative investments and co-investments by providing access to highly differentiated opportunities in these areas.

Share on Social Networks: